Affordable Access

Lymphocytosis decline is not responsible for tumor progression in cancer patients chronically treated with interleukin-2.

Authors
  • 1
  • 1 Divisione di Radioterapia Oncologia, Ospedale S. Gerardo, Monza, Italy. , (Italy)
Type
Published Article
Journal
Tumori Journal
0300-8916
Publisher
"Wichtig Publishing, SRL"
Publication Date
Volume
80
Issue
4
Pages
283–285
Identifiers
PMID: 7974799
Source
Medline
License
Unknown

Abstract

Despite the importance of lymphocytes in mediating the antitumor activity of IL-2, this study shows that tumor progression in cancer patients chronically treated with low-dose IL-2 after response or SD during IL-2 induction cycles is not associated with a significant decline in lymphocyte, T lymphocyte or NK cell numbers. Further studies, carried out to analyze the functional status of immune cells at the time of tumor progression, will be necessary to define the role of immunity in cancer patients progressing under IL-2 chronic therapy.

Statistics

Seen <100 times